Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
T-Cell Receptor (TCR) Engineered Cells and Their Transition to the Clinic
Mateusz Opyrchal
Section of Medical Oncology
Bursky Center for Human Immunology and Immunotherapy
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'T-Cell Receptor (TCR) Engineered Cells and Their Transition to the Clinic'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
T Cell Receptor
100%
Engineered Cells
100%
T Cells
75%
Clinical Trials
50%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Cell-based
25%
Genetic Modification
25%
Advanced Disease
25%
Durable Response
25%
Metastatic Disease
25%
Programmed Death-ligand 1 (PD-L1)
25%
Intracellular Protein
25%
Toxicity Data
25%
Solid Malignancies
25%
Efficacy Data
25%
MHC Molecules
25%
Cellular Products
25%
Off-target Toxicity
25%
Multiple Products
25%
Immune Modulation
25%
Continued Development
25%
Resistant to Treatment
25%
Patient numbers
25%
Advanced or Metastatic
25%
Autologous T Cells
25%
Medicine and Dentistry
T Cell
100%
T Lymphocyte Receptor
100%
Engineered Cell
100%
Clinical Trial
50%
Neoplasm
25%
Cancer
25%
Metastatic Carcinoma
25%
Cell Protein
25%
Chimeric Antigen Receptor T-Cell Immunotherapy
25%
Chimeric Antigen Receptor
25%
Diseases
25%
Peptide
25%
Immunology and Microbiology
T Cell
100%
T Cell Receptor
100%
Engineered Cell
100%
Chimeric Antigen Receptor
25%
Chimeric Antigen Receptor T-Cell Therapy
25%
Peptides
25%
Pharmacology, Toxicology and Pharmaceutical Science
T Lymphocyte Receptor
100%
Clinical Trial
50%
Chimeric Antigen Receptor
50%
Neoplasm
25%
Cell Protein
25%
Diseases
25%
Peptide
25%